Medscape Medical NewsAll articles

Lung Vision

BODY VISION MEDICAL LTD. • Radiology • 05/11/2017

510(k)IEC 62304 Class C
FDA Summary PDF

Device Purpose

The LungVision System is designed to support catheter and device navigation within the lungs during pulmonary procedures by segmenting pre-operative 3D CT scans and overlaying this anatomical data onto live fluoroscopic images. Its methodology leverages PC-based image processing for DICOM CT segmentation and co-registration with real-time fluoroscopy, offering visual guidance for endobronchial tool placement.

Summary

The LungVision System is an image processing tool developed to assist physicians during pulmonary procedures by improving the navigation of endobronchial tools. Its core function is to enable users to segment previously acquired 3D CT datasets, plan a target location and an access path within the lungs, and then overlay these segmented 3D datasets onto live fluoroscopic X-ray images of the patient's anatomy. This co-registration and overlay provide real-time visual support for guiding catheters or other medical devices toward the intended area of interest during the procedure. The system utilizes a PC-based hardware platform running proprietary image processing algorithms and software. Its main components include a laptop, a video capture box, an IEC 60601-1 compliant isolation transformer, a passive LungVision Board, and the LungVision software. Key technological capabilities encompass the segmentation of DICOM 3D CT image data, registration of this CT data with live fluoroscopic X-ray images, and the subsequent overlay of the segmented 3D CT dataset onto the live fluoroscopic view. Non-clinical bench testing confirmed that the system met all requirement specifications, including hazard mitigation and overall system performance, with specific tests using pig lungs to evaluate accuracy in deformable tissue. The system hardware complies with IEC 60601-1:2005 and IEC 60601-1-2:2014 standards.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

Lung NavigationImage-Guided Intervention3D CT SegmentationFluoroscopy OverlayPulmonary ProceduresEndobronchial ToolsMedical Image ProcessingReal-time GuidanceDICOMCatheter Navigation

Device Metadata

Submission Number
K163622
Company
BODY VISION MEDICAL LTD.
Panel
Radiology
Product Code
N/A
Data Type
Images
Clinical Function
Intervention
AI Function
Analysis
AI Subclass
quantification/feature localization

Relevant Clinical Questions

  • Q1. How does the system's accuracy in deformable tissue, as tested with pig lungs, translate to the dynamic environment of human breathing during a live procedure?; What is the typical time required for pre-procedure planning, including CT segmentation and path definition, using the LungVision System?; How does the LungVision System account for and mitigate potential registration inaccuracies between the static pre-acquired CT and the dynamic live fluoroscopy caused by patient movement or respiratory motion?; What specific image processing algorithms underpin the segmentation of 3D CT datasets and their registration with live fluoroscopic images, particularly concerning complex bronchial anatomies?; Are there comparative data on procedural efficiency, diagnostic yield, or patient outcomes when using the LungVision System versus unguided procedures or other navigation technologies for similar pulmonary interventions?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class C (software safety classification); Authorized before §524B enforcement

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score20/100
SBOM Evidence⚠ Not mentioned in summary
Cyber Risk Assessment⚠ Not mentioned in summary
Postmarket Plan⚠ Not mentioned in summary
§524B ApplicableNo

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials
- Not detected
ML-BOMMachine Learning Bill of Materials(algorithm, dataset)
✓ Detected
SaaSBOMSoftware-as-a-Service Bill of Materials(platform)
✓ Detected
HBOMHardware Bill of Materials(hardware)
✓ Detected
CBOMCryptography Bill of Materials
- Not detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials(environment)
✓ Detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of ML-BOM, SaaSBOM, HBOM, OBOM detected in AI-generated device summary.

• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.

• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.

• Not detected in AI-generated device summary: SBOM, CBOM, VDR/VEX. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
Lung Vision - BODY VISION MEDICAL LTD. | ESL FDA AI Device Intelligence